TickerFacts.

Company research / ENTA

Enanta Pharmaceuticals Inc (ENTA)

Build a valuation ↗↓ Download CSV

SEC name ENANTA PHARMACEUTICALS INC · CIK 0001177648 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Sep 30

For the year ended 2025-09-30, Enanta Pharmaceuticals Inc reported revenue of $65.32M. Revenue fell 3.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $65.26M.

Key ratios (year ended 2025-09-30)

-130.7%
Operating margin
-125.4%
Net margin
-126.5%
Return on year-end equity
-3.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-12

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-09-302024-09-302023-09-302022-09-302021-09-302020-09-302019-09-302018-09-302017-09-302016-09-30
Revenue$65.26M$65.32M$67.64M$79.20M$86.16M$97.07M$122.47M$205.20M$206.62M$102.81M$88.27M
R&D Expense$86.24M$106.74M$131.48M$163.52M$164.52M$174.11M$136.76M$142.21M$94.86M$57.45M$40.46M
Operating Income-$58.73M-$85.35M-$121.69M-$137.21M-$123.84M-$109.57M-$41.64M$36.74M$88.33M$24.61M$30.84M
Depreciation & Amortization$4.91M$4.59M$2.34M$2.37M$2.97M$3.33M$3.64M$3.26M$2.52M$2.14M$1.66M
EBITDA-$53.82M-$80.76M-$119.36M-$134.84M-$120.87M-$106.24M-$37.99M$40.00M$90.85M$26.75M$32.50M
Net Income-$63.23M-$81.89M-$116.05M-$133.82M-$121.75M-$79.00M-$36.17M$46.38M$71.96M$17.71M$21.67M
EPS (Diluted)n/a-$3.84-$5.48-$6.38-$5.91-$3.92-$1.81$2.21$3.48$0.91$1.13
Total Assets$296.87M$280.73M$376.65M$462.27M$375.41M$438.79M$486.13M$489.83M$414.23M$326.64M$281.28M
Total Liabilities$195.80M$216.01M$247.84M$245.54M$54.08M$39.36M$30.55M$27.34M$20.55M$24.96M$11.34M
Shareholders' Equity$101.07M$64.72M$128.81M$216.74M$321.33M$399.43M$455.58M$462.49M$393.68M$301.68M$269.94M
Cash & Equivalents$33.42M$32.30M$37.23M$85.39M$43.99M$57.21M$87.13M$51.23M$63.90M$65.67M$16.58M
Operating Cash Flow-$35.32M-$19.27M-$78.76M-$103.15M-$84.78M-$70.00M$7.09M$71.42M$29.22M$52.65M$35.81M
Capital Expenditures$1.62M$12.90M$17.95M$9.06M$2.12M$750.0K$1.45M$5.42M$2.98M$2.51M$4.74M
Free Cash Flow-$36.94M-$32.17M-$96.71M-$112.21M-$86.91M-$70.75M$5.64M$66.00M$26.24M$50.15M$31.07M
Shares Outstanding29.12M21.39M21.19M21.06M20.79M20.24M20.08M19.70M19.39M19.12M19.04M
Weighted Average Diluted Sharesn/an/an/an/an/a20.17M19.94M20.97M20.65M19.41M19.22M
EPS (Basic)n/a-$3.84-$5.48-$6.38-$5.91-$3.92-$1.81$2.37$3.74$0.93$1.14

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView